Retinal Vein Occlusion

Ophthalmology
6
Pipeline Programs
5
Companies
4
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 4 programs with unclassified modality

On Market (2)

Approved therapies currently available

Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
3 programs
1
AfliberceptPhase 41 trial
AfliberceptN/A
AfliberceptN/A
Active Trials
NCT01857544Unknown10Est. Mar 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
AtorvastatinPhase 3Small Molecule1 trial
Active Trials
NCT00517257UnknownEst. Sep 2009
Genentech
GenentechCA - Oceanside
1 program
1
ranibizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT01198327Completed66Est. Dec 2012
Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
fluocinolone acetonidePhase 11 trial
Active Trials
NCT00636493Completed30Est. May 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RegeneronAflibercept
Genentechranibizumab
PfizerAtorvastatin
Bausch + Lombfluocinolone acetonide

Clinical Trials (4)

Total enrollment: 106 patients across 4 trials

NCT01857544RegeneronAflibercept

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

Start: Jun 2013Est. completion: Mar 201610 patients
Phase 4Unknown
NCT01198327Genentechranibizumab

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

Start: Aug 2010Est. completion: Dec 201266 patients
Phase 3Completed
NCT00517257PfizerAtorvastatin

Atorvastatin for the Treatment of Retinal Vein Occlusion

Start: Aug 2007Est. completion: Sep 2009
Phase 3Unknown
NCT00636493Bausch + Lombfluocinolone acetonide

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

Start: Oct 2002Est. completion: May 200930 patients
Phase 1Completed

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Manager, Digital and Technology, Controllers Delivery

Pfizer
United States - New York - New York City
20h ago
$99K - $165K/yr

District Sales Manager (Virginia Beach, VA)

Globus Medical
Virginia
20h ago

Sr. Manager - EU Risk Management, SPRG

Johnson & Johnson
Beerse, Antwerp, Belgium
20h ago

Customer Order Management Specialist

Ferring Pharmaceuticals
Lisbon, Portugal
20h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)